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10 ABSTRACT: The interaction of Mn(ClO4)2·6H2O with salicylaldoxime
11 (H2sao) in the presence of nonsteroidal anti-inflammatory drug (NSAID)
12 sodium diclofenac (Nadicl) or indomethacin (Hindo) leads to the formation
13 of the hexanuclear Mn(III) clusters [Mn6(O)2(dicl)2(sao)6(CH3OH)6]
14 (1) and [Mn6(O)2(indo)2(sao)6(H2O)4] (2) both characterized as step-
15 ladder inverse-9-metallacrown-3 accommodating dicl− or indo− ligands,
16 respectively. When the interaction of MnCl2·4H2O with Nadicl or Hindo
17 is in the absence of H2sao, the mononuclear Mn(II) complexes
18 [Mn(dicl)2(CH3OH)4] (3) and [Mn(indo)2(CH3OH)4] (4) were iso-
19 lated. The complexes were characterized by physicochemical and spec-
20 troscopic techniques, and the structure of complexes 1 and 2 was char-
21 acterized by X-ray crystallography. Magnetic measurements (dc and ac)
22 were carried out in order to investigate the nature of magnetic
23 interactions between the magnetic ions and the overall magnetic behavior of the complexes.
1. INTRODUCTION
24 Polynuclear complexes of paramagnetic 3d- and 4f-metal ions
25 have received tremendous attention over the last three decades
26 or so, especially after the discovery that they can function
27 as single-molecule magnets (SMMs), exhibiting the properties
28 of bulk magnets but on the molecular level.1−7 After this dis-
29 covery, the synthesis of multifunctional molecular materials has
30 become one of the most appealing targets for synthetic
31 chemists and material scientists. Traditional multifunctional
32 systems, i.e., materials that combine multiple features, usually
33 include various composite or nanocomposite materials in which
34 one of the components plays the role of the matrix and the
35 other components with various tailored properties are
36 integrated into the matrix.8−11 The definition of multifunctional
37 molecular materials relies on the combination of two or more
38 physical properties in the same crystal lattice and covers a
39 variety of different compounds.12−14 One of our goals of this
40 interdisciplinary field of research is to synthesize and explore
41 new classes of coordination compounds that may exhibit, besides
42 single-molecule magnetism and ferromagnetism, important
43 biological activity.
44 Metallacrowns (MCs) are a class of polynuclear complexes,
45 which may be considered as molecular recognition agents and
46 can be considered as the inorganic analogues of organic crown
47 ethers. In brief, metallacrowns bear a cyclic structure analo-
48 gous to crown ethers where the methylene carbons have been
49replaced by transition-metal ions and nitrogen atoms;15,16 thus,
50the metallacrown ring is formed by repeating the [−O−N−M−]
51pattern. In regard to the 9-MC-3 metallacrowns, two structural
52motifs have been reported, i.e., regular, when the oxygen atoms
53are oriented toward the center of the MC cavity leading to
54encapsulation of metal cations, and inverse, when the metal
55atoms are located toward the center of the MC cavity, thus
56hosting anions.15,16 Hydroxamic acids and oximes are usually
57used as constructing ligands of the metallacrown rings. For
58most of the reported inverse metallacrowns, the constructing
59ligands are multidentate oximes such as di-2-pyridyl-ketonox-
60ime, phenyl-pyridyl-ketonoxime, and salicylaldoxime (H2sao,
61Figure 1A) or its derivatives, which can act as bifunctional
62ligands by providing the nitrogen and the oxygen atoms for the
63formation of the metallacrown ring.
64The doubly deprotonated ligand of salicylaldoxime (sao2−)
65is potentially a tridentate binucleating ligand, which may be
66coordinated to the metal ions via its nitrogen and oxygen atoms
67participating in the formation of the metallacrown ring. In the
68literature, there are plenty of polynuclear trivalent metal com-
69plexes with salicylaldoxime as ligands, where the metal ion
70is Fe(III)17,18 or, in most cases, Mn(III).19−29 Concerning the
71nuclearity of these complexes, the majority of the existing
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72 reports include dinuclear,17 trinuclear,20,25 tetranuclear,18,23 and
73 hexanuclear22−29 complexes hosting diverse ligands such as
74 amides,26 azides,27,28 halides,29 perchlorate,20 and diverse
75 carboxylate ligands.22−24
76 Nonsteroidal anti-inflammatory drugs (NSAIDs) are among
77 the most frequently used analgesic, anti-inflammatory, and anti-
78 pyretic agents despite their known gastrointestinal and renal
79 side effects.30 According to the characteristic chemical groups,
80 the chemical classes of NSAIDs include phenylalkanoate,
81 anthranilate, and salicylate derivatives bearing a carboxylic
82 group as well as oxicams, sulfonamides, and furanones.31 The
83 main biological target of the NSAIDs is the cyclooxygenase-
84 mediated production of prostaglandins,32 whereas NSAIDs
85 have shown synergism with respect to the activity of certain
86 antitumor drugs33 and have presented antitumor activity
87 leading to cell death in cancer cell lines via apoptosis34 or
88 other mechanisms.35,36 The study of the interaction with the
89 DNA (which is also a biological target of the anticancer drugs)
90 of NSAIDs and their compounds is of great importance as an
91 initial approach of their potential anti-inflammatory and anti-
92 cancer activity.37−39 Sodium diclofenac (Nadicl) and indome-
93 thacin (Hindo, Figure 1) are potent NSAIDs that belong to the
94 phenylalkanoic acid derivatives exhibiting favorable anti-
95 inflammatory, analgesic, and antipyretic properties,40−42 despite
96 gastrointestinal side effects such as ulceration and hemor-
97 rhage,43 which limit the dose of NSAIDs. Sodium diclofenac is
98 mainly used in painful and inflammation conditions such as
99 rheumatoid arthritis, spondilytis, and osteoarthritis.40 The
100 crystal structures of copper(II),44−47 manganese(II),48,49
101 cadmium(II),50 tin(IV),51 and nickel(II)52 complexes with
102 diclofenac ligands have been reported in the literature.
103 Indomethacin and its copper(II) complex are widely adminis-
104 tered in the clinical treatment of acute inflammation41 and
105 other medical conditions in humans.53 A series of Cu(II)54−57
106 and two tin complexes with indomethacin as a ligand58 have
107 been reported in the literature.
108 Manganese is among the most important biometals because
109 of its presence in the active center of many enzymes of diverse
110 functionality.59,60 The manganese-containing compounds
111 SC-52608 and Teslascan are used in medicine as anticancer
112 and MRI contrast agents, respectively.61 In the context of bio-
113 inorganic chemistry, manganese compounds have been exam-
114 ined for their anticancer,62−64 antimicrobial,65−68 antifungal,69
115 and antioxidant49,70 potencies, and in many cases, the results
116 were promising. Considering the metal-NSAID complexes,
117 there are reports on manganese complexes with the NSAIDs
118 diclofenac,48,49 mefenamic acid,71 niflumic acid,72 and tolfe-
119 namic acid.70
120Keeping in mind the biological significance of manga-
121nese59−61 and the tentative biological activity of the NSAIDs
122and their complexes,38,39,73 we present herein the synthesis and
123the characterization of the manganese complexes with the
124NSAIDs diclofenac and indomethacin in the presence or absence
125of H2sao. The presence of H2sao led to the formation of the
126hexanuclear complexes [Mn6(O)2(dicl)2(sao)6(CH3OH)6] (1)
127and [Mn6(O)2(indo)2(sao)6(H2O)4] (2), which may be con-
128sidered as inverse-[9-MC-3]2metallacrowns and were charac-
129terized by X-ray crystallography. The interaction of MnCl2·
1304H2O with the NSAIDs resulted in the mononuclear complexes
131[Mn(dicl)2(CH3OH)4] (3) and [Mn(indo)2(CH3OH)4] (4). All
132complexes were characterized by physicochemical (elemental
133analysis and molecular conductivity) and spectroscopic (IR
134and UV−vis) techniques. The overall magnetic behavior of
135compound 1 is ferromagnetic (FM), whereas at low temper-
136atures the zero-field effect is important. According to the fitting
137results of the susceptibility data, the ground state of the system
138is S = 4 with many low-lying excited states. Furthermore, alter-
139nating current (ac) magnetization measurements (both in-phase
140and out-of-phase) show strong frequency-dependent behavior,
141which is expected for an SMM. On the contrary, the overall
142magnetic behavior of compound 2 is antiferromagnetic (AFM)
143with no ac signals indicating a non-SMM character.
2. EXPERIMENTAL SECTION
1442.1. Materials, Instrumentation, and Physical Measure-
145ments. Sodium diclofenac, indomethacin, salicylaldoxime, MnCl2·
1464H2O, Mn(ClO4)2·6H2O, MeONa, and KOH were purchased from
147Sigma-Aldrich, and all solvents were purchased from Chemlab. All
148chemicals and solvents were reagent grade and were used as purchased
149without any further purification. Caution! Perchlorate salts can be
150explosive and should be handled with care.
151Infrared spectra (400−4000 cm−1) were recorded on a Nicolet
152FT-IR 6700 spectrometer with samples pa relatively smallerrepared as
153KBr disks. UV−vis spectra were recorded as Nujol mulls and in
154DMSO solution at concentrations in the range of 10−5−10−3 M on
155a Hitachi U-2001 dual-beam spectrophotometer. Room-temperature
156magnetic measurements for complexes 3 and 4 were carried out on a
157magnetic susceptibility balance from Sherwood Scientific (Cambridge,
158U.K.). C, H, and N elemental analyses were performed on a PerkinElmer
159240B elemental analyzer. Molar conductivity measurements of 1 mM
160DMSO solution of the complexes were carried out with a Crison Basic
16130 conductometer.
162Magnetic measurements for complexes 1 and 2 were carried out in
163the Unitat de Mesures Magnet̀iques (Universitat de Barcelona) with a
164Quantum Design SQUID MPMS-XL magnetometer equipped with
165a 5 T magnet. Pascal’s constants were used to estimate diamagnetic
166corrections to the molar paramagnetic susceptibility. The magnetic
167data analysis and fittings were carried out using the PHI program.74
Figure 1. Syntax formula of (A) salicylaldoxime (H2sao), (B) sodium diclofenac (Nadicl), and (C) indomethacin (Hindo).
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168 2.2. Synthesis of the Complexes. 2.2.1. Synthesis of
169 [Mn6(O)2(dicl)2(sao)6(MeOH)6] (1). A methanolic solution (10 mL)
170 containing H2sao (41 mg, 0.3 mmol) and MeONa (32 mg, 0.6 mmol)
171 was stirred for 1 h and added simultaneously with a methanolic solu-
172 tion (10 mL) of Nadicl (29 mg, 0.4 mmol) to a methanolic solution
173 (10 mL) of Mn(ClO4)2·6H2O (108 mg, 0.3 mmol). The resultant
174 solution was left for slow evaporation after 1 h of stirring. Dark-brown
175 well-formed crystals of [Mn6(O)2(dicl)2(sao)6(MeOH)6] (59 mg,
176 60%) suitable for X-ray structure determination were collected after
177 a week. Anal. Calcd for [Mn6(O)2(dicl)2(sao)6(MeOH)6] (1)
178 (C76H74Cl4Mn6N8O24) (MW = 1954.84): C 46.69, H 3.82, N 5.73;
179 found C 46.51, H 4.01, N 5.95. IR (KBr pellet), νmax/cm
−1:
180 ν(CN)sao, 1598 (very strong (vs)); ν(NO)sao, 1440 (strong
181 (s)); νasym(CO2)dicl, 1586 (vs); νsym(CO2)dicl, 1388 (vs); Δν(CO2) =
182 νasym(CO2) − νsym(CO2) = 198 cm−1. UV−vis, as a Nujol mull, λ/nm:
183 648(shoulder (sh)), 385 (sh), 287. In DMSO, λ/nm (ε/M−1cm−1):
184 650 (580), 390 (1900), 289 (14 000). The compound is soluble in
185 N,N-dimethylformamide (DMF) and dimethyl sulfoxide (DMSO)
186 (ΛM = 8 S·cm2·mol−1, in 1 mM DMSO solution).
187 2.2.2. Synthesis of [Mn6(O)2(indo)2(sao)6(H2O)4] (2). Complex 2
188 was prepared by a similar procedure. More specifically, a methanolic
189 solution (30 mL) of indomethacin (36 mg, 0.1 mmol), MeONa (38 mg,
190 0.7 mmol), and H2sao (41 mg, 0.3 mmol) was stirred for 1 h and added
191 to a methanolic solution (10 mL) of Mn(ClO4)2·6H2O (108 mg,
192 0.3 mmol). The resultant solution was stirred for 1 h and left for slow
193 evaporation. Dark-brown crystals of [Mn6(O)2(indo)2(sao)6(H2O)4]
194 (2) (72 mg, 70%) suitable for X-ray structure determination were
195 collected after a week. Anal. Calcd for [Mn6(O)2(indo)2(sao)6(H2O)4]
196 (C80H72Cl2Mn6N8O28) (MW = 1993.96): C 48.19, H 3.64, N
197 5.62; found C 47.89, H 3.82, N 5.73. IR (KBr pellet), νmax/cm
−1:
198 ν(CN)sao, 1598 (vs); ν(NO)sao, 1439 (s); νasym(CO2)indo, 1560
199 (vs); νsym(CO2)indo, 1373 (vs); Δν(CO2) = 187 cm−1. UV−vis, as a
200 Nujol mull, λ/nm: 650 (sh), 312 (sh), 287. In DMSO, λ/nm
201 (ε/M−1cm−1): 647 (600), 316 (sh) (4500), 290 (13 500). The com-
202 pound is soluble in methanol, DMF, and DMSO (ΛM = 6 S·cm2·mol−1
203 in 1 mM DMSO solution) and partially soluble in H2O.
204 2.2.3. Synthesis of [Mn(dicl)2(MeOH)4] (3). Complex 3 was
205 prepared by the addition of Nadicl (159 mg, 0.5 mmol) dissolved in
206 MeOH (10 mL) to a methanolic solution (10 mL) of MnCl2·4H2O
207 (0.25 mmol, 50 mg) followed by 1 h of stirring. The colorless
208 microcrystalline product of [Mn(dicl)2(MeOH)4] (100 mg, 55%) was
209 collected after 2 weeks from the resultant solution. Anal. Calcd
210 for [Mn(dicl)2(MeOH)4] (C32H36Cl4MnN2O8) (MW = 773.40): C
211 49.70, H 4.69, N 3.62; found C 49.57, H 4.52, N 3.73. IR (KBr pellet),
212 νmax/cm
−1: νasym(CO2)dicl, 1587 (vs); νsym(CO2)indo, 1379 (vs);
213 Δν(CO2) = 208 cm−1. UV−vis, as a Nujol mull, λ/nm: 290. In
214 DMSO, λ/nm (ε/M−1cm−1): 290 (22 000). μeff at room temperature =
215 5.95μB The complex is soluble in methanol, DMF, and DMSO (ΛM =
216 9 S·cm2·mol−1 in 1 mM DMSO solution).
217 2.2.4. Synthesis of [Mn(indo)2(MeOH)4] (4). A methanolic solu-
218 tion (10 mL) containing indomethacin (180 mg, 0.5 mmol) and KOH
219 (0.5 mmol, 28 mg) was stirred for 1 h in order to deprotonate
220 indomethacin. The solution was added dropwise to a methanolic
221 solution (10 mL) of MnCl2·4H2O (0.25 mmol, 50 mg) and the
222 resultant solution was stirred for 30 min. Colorless microcrystalline
223 product of [Mn(indo)2(MeOH)4] (125 mg, 60%) precipitated
224 after 10 days and was collected by filtration. Anal. Calcd for
225 [Mn(indo)2(MeOH)4] (C42H46Cl2MnN2O12) (MW = 896.68): C
226 56.26, H 5.17, N 3.12; found C 55.96, H 5.01, N 3.21. IR (KBr pellet),
227 νmax/cm
−1: νasym(CO2)indo, 1599 (vs); νsym(CO2)indo, 1392 (vs);
228 Δν(CO2) = 207 cm−1; UV−vis, as a Nujol mull, λ/nm: 318 (sh),
229 275. In DMSO, λ/nm (ε/M−1cm−1): 320 (10 500), 277 (20 900). μeff
230 at room temperature = 6.05μB. The complex is soluble in methanol,
231 DMF, and DMSO (ΛM = 8 S·cm2·mol−1 in 1 mM DMSO solution).
232 2.3. X-ray Structure Determination. Single crystals from com-
233 pounds 1 and 2 were selected, separated from their mother liquor, and
234 mounted on a Bruker Kappa APEX 2 diffractometer equipped with a
235 triumph monochromator using Mo Kα radiation. Cell dimension
236 refinement was accomplished using the settings of at least 120 high
237 θ reflections with I ≥ 20σ(I). The crystals presented no decay during
238the data collection. The frames collected (running φ and ω scans)
239were integrated with the Bruker SAINT Software package75 using a
240narrow-frame algorithm. Data were corrected using the SADABS
241program.76 The structures were solved by the SUPERFLIP package77
242incorporated into Crystals. The Crystals version 14.40 program
243package78 has been used for the refinement and all subsequent
244calculations through full-matrix least squares on F2. All non-hydrogen
245atoms, except the disordered water oxygen atoms, have been refined
246anisotropically. All hydrogen atoms were found at their expected
247positions and refined using proper riding constraints to the pivot
248atoms. Molecular illustrations were drawn using CAMERON.79
249Crystallographic details are summarized in Table S1.
3. RESULTS AND DISCUSSION
2503.1. Synthesis Considerations. Structurally characterized
251compounds 1 and 2 consist of two inverse-[9-MC-3] cores
252accommodating diclofenac or indomethacin anions, respec-
253tively, and show similar geometrical features. Complexes 1 and
2542 were isolated in high yield by the reaction of a mixture
255containing equimolar quantities of Mn(ClO4)2·6H2O and sao
2−
256in methanol in the presence of sodium salt of the NSAID in a
257Mn2+/sao2−/NSAID− ratio of 3:3:1 at room temperature. The
258isolated compounds are crystalline and dark brown and are
259soluble in DMSO, being nonelectrolytes (ΛM = 6−8 S·cm2·mol−1,
2601 mM in DMSO).
261Compounds 3 and 4 were prepared via the aerobic reaction
262of MnCl2·4H2O with the sodium salt of the NSAID in meth-
263anol in a 1:2 Mn2+/NSAID− ratio at room temperature. The
264colorless compounds are soluble in DMSO and nonelectrolytes
265(ΛM = 8−9 S·cm2·mol−1, 1 mM in DMSO).
266Complexes 1−4 were characterized by elemental analysis,
267IR and UV−vis spectroscopy, and magnetic measurements. The
268structures of compounds 1 and 2 were determined by X-ray
269crystallography.
2703.2. Structures of Complexes 1 and 2. Structurally
271characterized compounds 1 and 2 consist of two inverse-[9-
272MC-3] metallacrown cores accommodating diclofenac or indo-
273methacin anions, respectively, and show similar geometrical
274features. Each [9-MC-3] metallacrown ring consists of three
275Mn(III) atoms and three salicylaldoximato ligands as the
276constructing ligands. The salicylaldoximato ligands are doubly
277deprotonated (sao2−) and act as tridentate binucleating ligands
278being coordinated to a Mn(III) atom via the salicylato oxygen
279(Osal) and oximato nitrogen forming a six-membered chelate
280ring and to an adjacent Mn(III) atom via the oximato oxygen
281(Oox) (Figure 2). The unit [Mn−N−Oox] is repeated three
282times, creating the nine-membered metallacrown ring. The
283metallacrown core is characterized as inverse because the man-
284ganese(III) atoms, instead of the oxygen atoms, are oriented
285toward the central cavity.
2863.2.1. Crystal Structure of Complex 1. The molecular
287structure of complex 1 is depicted in Figure 3, and important
288bond lengths and angles are given in Tables 1 and S2,
289respectively. The complex consists of two [9-MC-3] metal-
290lacrown rings, two diclofenac ligands, and six methanol ligands.
291The specific connectivity of the atoms forming the ring is
292Mn(1)−O(2)−N(3)−Mn(4)−O(12)−N(11)−Mn(6)−O(19)−
293N(20), and the average bond distances of the ring are
294Mn−Oox = 1.918 Å (in the range 1.896(2)−1.9404(17) Å),
295Mn−N = 1.996 Å (in the range 1.991(2)− 2.003(2) Å), and
296N−Oring = 1.372 Å (in the range 1.360(3)−1.386(3) Å). The
297bond valence sum values for the Mn atoms in complex 1 are
2983.05 (for Mn1), 3.03 (for Mn4), and 2.96 (for Mn6) and verify
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299 that all Mn atoms are in the +3 oxidation state, as calculated by









302 where Rij is the length, Sij is the valence of the bond between
303 atoms i and j, and R0 and b are the empirically determined bond
304 valence parameters (for Mn, R0 = 1.75 and b = 0.37).
82 The
305 ring Mn(III)···Mn(III) separation distance is 3.26 Å with the
306three ring Mn(III) atoms forming an equilateral triangle. The
307crystal structure of the complex contains two nine-membered
308inverse metallacrown rings of the type [9-MCMn(III)N(sao)-3] in a
309stepladder-like arrangement. The metallacrown rings are
310bonded via two ring oximato oxygen atoms (O(12) and
311O(12)′), creating the binuclear moiety [Mn(4)−O(12)−
312Mn(4)′−O(12)′] with a planar arrangement [the sum of
313the angles O(12)−Mn(4)−O(12)′ (= 80.31(7)°), Mn(4)′−
314O(12)−Mn(4) (= 99.69(7)°), O(12)−Mn(4)′−O(12)′
315(= 80.31(7)°), and Mn(4)′−O(12)′−Mn(4) (= 99.69(7)°) is
316almost 360.0(7)°] and a Mn(4)···M(4)′ distance equal to
3173.3827(5) Å. The arrangement of the six Mn(III) atoms of the
318complex is distorted trigonal antiprismatic with the three
319Mn(III) atoms of each metallacrown ring forming the bases;
320the bases’ centroid-to-centroid distance is equal to 4.876 Å, and
321the bases’ plane-to-plane distance is 3.006 Å. Taking into
322consideration the average ionic radius of Mn(III) (= 0.75 Å),83
323the space in the metallacrown cavity is such that it allows
324the encapsulation of an O2− ligand (ionic radius = 1.26 Å),83
325which is bound to the three ring Mn(III) atoms at an average
326Mn−O(5) distance of 1.8865 Å (in the range 1.8792(17)−
3271.8938(17) Å), and it is almost coplanar with the three Mn(III)
328atoms of the metallacrown ring (∼0.10 Å out of the Mn(III)3
329plane).
330The coordination environment and the geometry of the
331Mn(III) atoms are different. Mn(1) and Mn(4) bear a NO5
332chromophore and have a Jahn−Teller distorted octahedral
333geometry with the Jahn−Teller axis being vertical to the plane
334formed from the three Mn(III) atoms, i.e., Mn(1), Mn(4), and
335Mn(6) atoms. Mn(1) has a planar structure with four short
336distances (Mn(1)−(N/O)av = 1.914 Å) and two long distances
337(Mn(1)−Oav = 2.289 Å), exhibiting an elongated octahedral
338geometry with atoms O(2), O(5), O(24), and N(20) located at
339the equatorial positions of the octahedron and O(56) and
340O(58) lying at the axial positions of the octahedron. Mn(4)
341also has a planar configuration with four short distances
342(Mn(4)−(N/O)av = 1.927 Å) with O(5), O(12), O(29), and
343N(3), which form the basis of the octahedron, an intermedi-
344ate (Mn(4)−O(37) = 2.1082(19) Å), and a long distance
345(Mn(4)−O(12)′ = 2.4635(18)Å) where atoms O(37) and
346O(12)′ are located at the axial positions of the asymmetrically
347elongated octahedron. Mn(6) has a NO4 coordination
348environment with a slight distortion from the regular square-
349based pyramidal geometry as concluded from the value of the
350trigonality index,84 τ = (177.39(8) − 169.69(9))/60 = 0.128
351[τ = (φ1 − φ2)/60°, where φ1 and φ2 are the largest angles in
352the coordination sphere; τ = 0 for a perfect square pyramid;
353τ = 1 for a perfect trigonal bipyramid]. N(11), O(5), O(7), and
354O(19) form the basis of the square pyramid, and O(17) lies at
355the apex of the pyramid. The elongation of the tetragonal
356pyramid on Mn(6) also has the same orientation with respect
357to the Jahn−Teller axis on Mn(1) and Mn(4).
358The two diclofenac ligands are deprotonated by being
359monodentately bound to Mn(4) via the carboxylato oxygen
360atoms O(37) [Mn(4)−O(37) = 2.1082(19) Å]. The coordina-
361tion spheres of Mn(6) and Mn(1) are completed by one and
362two OM atoms, respectively, from the six methanol ligands of
363the complex at an average Mn−OM distance of 2.234 Å (in the
364range 2.166(2)−2.302(2) Å).
3653.2.2. Crystal Structure of Complex 2. The molecular
366structure of complex 2 is depicted in Figure 4, and important
367bond lengths and angles are given in Tables 2 and S3, respec-
368tively. The complex consists of two [9-MC-3] metallacrown
Figure 2. [9-MC-3] metallacrown ring found in the structures of
complexes 1 and 2.
Figure 3. Molecular structure of complex 1.






Mn(1)−O(2) 1.905(2) Mn(4)−O(5) 1.8796(17)
Mn(1)−O(5) 1.8938(17) Mn(4)−O(12) 1.9404(17)
Mn(1)−O(24) 1.864(2) Mn(4)−O(12)′ 2.4629(19)
Mn(1)−O(56) 2.302(3) Mn(4)−O(37) 2.1082(19)
Mn(1)−O(58) 2.277(2) Mn(4)−O(29) 1.8973(18)
Mn(1)−N(20) 1.993(2) Mn(4)−N(3) 1.991(2)
Mn(6)−O(5) 1.8792(17) Mn(6)−O(17) 2.166(2)
Mn(6)−O(7) 1.8560(19) Mn(6)−O(19) 1.896(2)
Mn(6)−N(11) 2.003(2) O(12)−N(11) 1.386(3)
O(2)−N(3) 1.360(3) O(19)−N(20) 1.369(3)
Mn(1)···Mn(4) 3.2604(6) Mn(1)···Mn(6) 3.2591(7)
Mn(4)···Mn(6) 3.2590(6) Mn(4)···Mn(4)′ 3.3827(5)
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369 rings, two indomethacin ligands, and four aqua ligands. The
370 arrangement and the coordination of the sao2− ligands in the
371 inverse metallacrown ring of complex 2 are similar to that of
372 complex 1. The connectivity of the atoms forming the ring is
373 Mn(1)−O(55)−N(54)−Mn(3)−O(4)−N(5)−Mn(6)−
374 O(40)−N(41), and the average bond distances of the ring are
375 Mn−Oox = 1.923 Å, Mn−N = 2.022 Å, and N−Oring = 1.373 Å.
376 The bond valence sum values for the Mn atoms in complex 2 as
377 calculated with eq 1 are 2.95 (for Mn1), 2.94 (for Mn3), and
378 2.95 (for Mn6), verifying that the oxidation state of all Mn
379 atoms is +3. In contrast to 1, the three ring Mn(III)···Mn(III)
380 separation distances are not equal, having an average distance of
381 3.247 Å with two almost equal distances (Mn(1)···Mn(3) =
382 3.2927(11) Å and Mn(1)···Mn(6) = 3.2863(12) Å) forming an iso-
383 sceles triangle (the third side is Mn(3)···Mn(6) = 3.1610(13) Å).
384 The two ring oximato oxygen atoms (O(4) and O(4)′) are
385 the bridging atoms between the two nine-membered metal-
386 lacrown rings forming the binuclear moiety [Mn(3)−O(4)−
387 Mn(3)′−O(4)′] with a distance Mn(3)···M(3)′ = 3.4247(15)
388 Å, and the sum of the four angles is 360.00(8)° (O(4)−
389 Mn(3)−O(4)′ = 78.49(8)°, Mn(3)−O(4)−Mn(3)′ =
390 101.51(8)°, O(4)−Mn(3)′−O(4)′ = 78.49(8)°, and Mn(3)−
391 O(4)′−Mn(3)′ = 101.51(8)°), which indicates a planar
392 arrangement. The distorted trigonal antiprismatic arrangement
393 of the six Mn(III) atoms of the complex has a centroid-to-
394 centroid distance between the two bases formed by the three
395 Mn(III) atoms of each metallacrown ring equal to 5.302 Å and
396 a plane-to-plane distance equal to 3.240 Å. Oxygen atom O(2)
397 is the encapsulated O2− ligand in the metallacrown cavity
398 1.8846 Å (average distance) from the three ring Mn(III) atoms,
399 and it is displaced ∼0.18 Å out of the [Mn(III)3] plane.
400Mn(1) and Mn(3) have a NO5 coordination environment
401with a distorted octahedral geometry. Mn(1) has a planar
402configuration with four short distances (Mn(1)−(N/O)av =
4031.927 Å) and two long distances (Mn(1)−Oav = 2.302 Å),
404exhibiting a Jahn−Teller elongated octahedral geometry with
405O(2), O(55), O(49), and N(51) located at the equatorial
406positions of the octahedron and O(60) and O(62) lying at the
407axial positions of the octahedron. The configuration of Mn(3)
408with four short distances (Mn(3)−(N/O)av = 1.8979 Å) and
409two long distances (Mn(3)−O(17) = 2.1462(17)Å, Mn(3)−
410O(4)′ = 2.4458(17) Å) with O(2), O(4), O(50) and N(54) is
411similar, forming the basal plane of the octahedron, with O(4)′
412and O(17) being at the apical positions of the asymmetri-
413cally elongated octahedron. Mn(6) with a NO4 chromophore
414presents a slightly distorted square-based pyramidal geometry
415with a value of the trigonality index of τ = (166.89(8) −
416164.43(8))/60 = 0.041, where N(5), O(2), O(7), and O(40)
417form the basis of the square pyramid and O(15) lies at the apex
418of the pyramid.
419The two deprotonated indomethacin ligands are bidentate
420μ1,3-bridging ligands bound to Mn(3) and Mn(6) via the car-
421boxylato oxygen atoms O(17) (Mn(3)−O(17) = 2.1462(17)Å)
422and O(15) (Mn(6)−O(15) = 2.1137(19) Å), respectively. The
423coordination sphere of Mn(1) is completed by two Ow atoms
424from the aqua ligands at an average Mn(1)−Ow distance of
4252.316 Å.
4263.3. Spectroscopic Characterization of the Com-
427plexes. The IR spectra of complexes 1 and 2 exhibit char-
428acteristic bands attributed to ν(CN)pyridyl (1598 cm−1) and
429ν(NO) (1439−1440 cm−1) of the sao2− ligand participating
430in the formation of the metallacrown ring.47 Additionally, in the
431IR spectra of complexes 1−4, the bands attributed to the
432antisymmetric and the symmetric stretching vibrations,
433νasym(CO2) and νsym(CO2) of the carboxylato groups of the
434NSAID ligands, are located at 1560−1599 and 1373−
4351392 cm−1, respectively. The difference Δν(CO2) [= νasym(CO2)
436− νsym(CO2)] is a useful characteristic tool for determining the
437coordination mode of the carboxylato ligands.85 For complexes
4381, 3, and 4, Δν(CO2) is found in the range 198−208 cm−1 and
439higher than that found in the sodium salt of the corresponding
440NSAID (Δν(CO2) = 192−194 cm−1), indicating an asym-
441metric monodentate binding mode of the carboxylato group of
442the NSAID,86 whereas for complex 2, the calculated Δν(CO2)
443value is 187 cm−1, suggesting the existence of a bidentate
444coordination mode.85,86
445The UV−vis spectra of the complexes were recorded as
446Nujol mull and in DMSO solution and are similar, suggest-
447ing that the complexes retain their structure in solution.
448In addition, the complexes do not dissociate in solution (ΛM =
4496−9 S·cm2·mol−1) and have the same UV−vis spectral patterns
450in DMSO solution and in the presence of the buffer solution
451used in the biological experiments, suggesting that they keep
452their integrity in solution.47,87
4533.4. Magnetic Measurements of the Compounds.
4543.4.1. dc Magnetic Measurements of Compound 1. The
455temperature dependence of the susceptibility data in the form
456of χMT for complex 1 is shown in Figure 5. The value of χMT at
457room temperature is 16.428 cm3·mol−1·K and increases while
458the temperature decreases to the value of 20.982 cm3·mol−1·K
459at 10 K. After that temperature, there is an abrupt decrease to
460the value of 7.776 cm3·mol−1·K at 2 K. The overall magnetic
461behavior of this complex is ferromagnetic, whereas at low
462temperatures the zero-field effect is important.
Figure 4. Molecular structure of complex 2.






Mn(1)−O(2) 1.8994(15) Mn(3)−O(2) 1.8716(14)
Mn(1)−O(49) 1.8788(17) Mn(3)−O(4)′ 2.4458(17)
Mn(1)−O(55) 1.9242(16) Mn(3)−O(4) 1.9581(17)
Mn(1)−O(60) 2.219(2) Mn(3)−O(17) 2.1462(17)
Mn(1)−O(62) 2.412(2) Mn(3)−O(50) 1.8906(15)
Mn(1)−N(41) 2.0075(19) Mn(3)−N(54) 2.029(2)
Mn(6)−O(2) 1.8828(16) Mn(6)−O(40) 1.8953(15)
Mn(6)−O(7) 1.8652(17) Mn(6)−N(5) 2.0297(18)
Mn(6)−O(15) 2.1137(19) O(55)−N(54) 1.377(2)
O(4)−N(5) 1.379(2) O(40)−N(41) 1.364(2)
Mn(1)···Mn(6) 3.2863(12) Mn(1)···Mn(3) 3.2927(11)
Mn(3)···Mn(6) 3.1610(13) Mn(3)···Mn(3)′ 3.4247(15)
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463 According to the literature,88−91 torsion angles above 31° will
464 promote ferromagnetic coupling, whereas below 31° anti-
465 ferromagnetic coupling is revealed. Two of the three torsion
466 angles between the Mn(III) ions are smaller than 31° (Mn(1)−
467 N(20)−O(19)−Mn(6) = 16.72°, Mn(1)−O(2)−N(3)−
468 Mn(4) = 19.23°, Mn(4)−O(12)−N(11)−Mn(6) = 32.28°),
469 indicating that the magnetic interactions through the oximato
470 bridge are antiferromagnetic and the interactions between
471 the Mn(4)−Mn(6)/Mn(4′)−Mn(6′) and between the Mn(4)−
472 Mn(4′) ions are ferromagnetic. Thus, the Hamiltonian chosen to
473 fit the magnetic susceptibility data is shown in eq 2 and
474 contains J1 between the Mn(4)−Mn(6)/Mn(4′)−Mn(6′) and
475 J3 between the Mn(4)−Mn(4′) ions as a ferromagnetic
476 exchange constant whereas J2 (oximato bridge) as is the AFM
477 one (the magnetic model is shown in Figure S1). The values of
478 J1, J2, J3, and g obtained from the fitting process (solid line in
479 Figure 5) are J1 = +0.89 cm
−1, J2 = −0.17 cm−1, J3 = +1.28 cm−1,
480 and g = 1.92, in agreement with those reported in the
481 literature.88−91
= − + − + + +
−




2 (S S S S ) 2 (S S S S S S S S )
2 S S
1 4 6 4 6 2 1 4 4 6 1 4 4 6
3 4 4482 (2)
483 According to the fitting results of the susceptibility data, the
484 ground state of the system is S = 4 with many low excited states
485 (S = 5 at 0.8 cm−1, S = 6 at 1.9 cm−1), indicating a nonisolated
486 ground state. This was further confirmed by the lack of fitting
487 results of the magnetization data at 2 K using the giant spin
488 model (Figure S2).
489 3.4.2. Alternating Current Magnetic Measurements of
490 Compound 1. Dynamic ac magnetization measurements with
491 frequencies ν in the 10−1500 Hz range have been performed in
492 order to clarify the nature of the magnetic state of compound 1
493 and are shown in Figure 6. The thermal variation of the
494 ac susceptibility shows rounded peaks for both the real and
495 imaginary parts, whereas for both components a second peak
496 seems to appear. Both in-phase and out-of-phase components
497 show strong frequency-dependent behavior. χ′ and χ″ shift to
498 lower temperatures for lower frequencies, which is expected for
499 an SMM. The temperature dependence of the relaxation time
500 τ(t) follows the Arrhenius law: τ(t) = τo exp(Ueff/kBT) and is
501 shown in Figure 6 in the form of ln(τ) versus 1/T, where τo is a
502 prefactor and Ueff is the activation barrier. The fitted procedure
503gave the values Ueff/kB = 41 K and τo = 3.87 × 10
−10 s in the
504range expected for SMM systems.88−91
5053.4.3. dc Magnetic Measurements of Compound 2. The
506temperature dependence of the susceptibility data in the form
507of χMT for complex 2 is shown in Figure 7. The value of χMT at
508room temperature is 16.853 cm3·mol−1·K and decreases with the
509decrease in temperature to a minimum of 7.358 cm3·mol−1·K at
51014 K. After that temperature, there is an abrupt increase to the
511value of 11.046 cm3·mol−1·K at 2 K. The overall magnetic
Figure 5. Temperature dependence of the susceptibility data in the
form of χMT vs T for complex 1. The solid line represents the fitting
results according the magnetic model shown in eq 2 (details in the
text).
Figure 6. Temperature dependence ac magnetic susceptibility (real χ′
and imaginary χ″ susceptibility components) for compound 1 in an
oscillating field of 5 Oe and a 0 dc field and for frequencies 10, 100,
500, 1000, 1500 Hz. (The arrow shows the trend in frequencies
starting from the lowest value, i.e., 10 Hz). The inset shows the
Arrhenius plot with the fitting results. (See the text for details.)
Figure 7. Temperature dependence of the susceptibility data in the
form of χMT vs T for complex 2. The solid line represents the fitting
results according to eq 3. (See text for details.)
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512 behavior of this complex is antiferromagnetic. Two torsion
513 angles between the Mn(III) ions are smaller than 31° (Mn(1)−
514 N(41)−O(40)−Mn(6) = 7.60°, Mn(6)−N(5)−O(4)−Mn(3) =
515 15.93°), which may promote antiferromagnetic interactions
516 between these magnetic ions. AFM interactions are also favored
517 because of the syn-syn-carboxylato bridges in the complex. The
518 existence of a torsion angle higher than 31° (Mn(1)−O(55)−
519 N(54)−Mn(3) = 32.23°) may give rise to ferromagnetic inter-
520 actions between the Mn(1)−Mn(3) ions. Since there is a
521 syn-syn-carboxylate bridge, which would give AFM coupling,
522 and a torsion angle of 32.23° between Mn(1) and Mn(3)
523 ions that promotes FM coupling, a 4J exchange coupling
524 Hamiltonian was tried (H = −2J1(S3S6 + S3′S6′) − 2J2(S1S6 +
525 S1′S6′) − 2J3S3S3′ − 2J4(S1S3 + S1′S3′)). However, the fitting
526 results led to the same AFM values for J1 and J4. Thus, the fit
527 was finally performed with a 3J Hamiltonian described by eq 3,
528 and the magnetic model is shown in Figure S3. As can be
529 observed, the only FM coupling (J3) takes place between
530 Mn(3) and Mn(3′), whereas the expected FM between Mn(1)
531 and Mn(3) (due to the torsion angle) is not observed. The
532 oximato and syn-syn-carboxylate bridges give rise to the AFM
533 coupling J2 and J1, respectively.
= − + − + + +
−




2 (S S S S ) 2 (S S S S S S S S )
2 S S
1 3 6 3 6 2 1 6 1 3 1 6 1 3
3 3 3534 (3)
535 The values of the J1, J2, J3, and g obtained from the fitting pro-
536 cess (solid line in Figure 7) are J1 = −1.27 cm−1, J2 = −4.9 cm−1,
537 J3 = +1.4 cm
−1, and g = 2.09, in agreement with those reported
538 in the literature.88−91
539 According to the fitting results of the susceptibility data, the
540 ground state of the system is S = 4, which is not well iso-
541 lated from the next excited S = 3 state (4.3 cm−1). Fitting
542 of the magnetization data at 2 K using a giant spin model of an
543 S = 4 spin gave poor results (Figure S4).
544 No ac signals were observed for this compound, indicating a
545 non-SMM character.
546 3.4.4. Room Temperature Magnetic Measurements for
547 Compounds 3 and 4. The magnetic measurements for com-
548 plexes 3 and 4 were performed at room temperature. The
549 observed values μeff (= 5.95−6.05 μB) for the complexes are
550 close to the spin-only value (= 5.92 MB) at room temperature
551 and are typical for mononuclear high-spin Mn(II) complexes
552 with a d5 configuration (S = 5/2).92,93
553 3.5. Proposed Structures for Complexes 3 and 4.
554 Despite our efforts (diverse solvents and mixtures of them as
555 well as diverse crystallization conditions were used), we did not
556 manage to get single crystals of complexes 3 and 4 suitable for
557 X-ray crystallography. Therefore, we have characterized these
558 complexes on the basis of existing elemental analysis, magnetic
559 measurements, and IR spectroscopic data. According to the
560 results derived from the room-temperature magnetic data,
561 complexes 3 and 4 are neutral mononuclear. According to
562 IR spectroscopic data, the NSAID ligands are deprotonated and
563 are bound to the manganese ion in a monodentate fashion via a
564 carboxylato oxygen atom. Complexes 3 and 4 are expected to
565 have similar structures with complex [Mn(nif)2(MeOH)4],
72
566 where Hnif is NSAID niflumic acid being coordinated to Mn in
567 a monodentate mode. Similarly, complexes 3 and 4 have a
568 MnO6 chromophore and the centrosymmetric coordination
569 sphere around the six-coordinate Mn consists of two oxygens
570 from the NSAID ligands and four oxygen atoms from the
571 methanol ligands (Figure 8).
4. CONCLUSIONS
572In our search for multifunctional materials that may exhibit,
573besides single-molecule magnetism, important biological
574activity, we investigated the interaction of Mn(ClO4)2 with
575doubly deprotonated salicylaldoxime in the presence of the
576NSAIDs sodium diclofenac or indomethacin resulting in the
577formation of the hexanuclear Mn(III) clusters [Mn6(O)2-
578(dicl)2(sao)6(CH3OH)6] (1) or [Mn6(O)2(indo)2(sao)6(H2O)4]
579(2) respectively, which both may also be characterized as
580stepladder inverse-9-metallacrown-3 complexes. Furthermore,
581compound 1 is characterized as a single-molecule magnet,
582exhibiting strong frequency-dependent behavior with an
583activation barrier of Ueff = 41 K, whereas compound 2 has
584overall antiferromagnetic behavior and non-SMM character. The
585mononuclear Mn(II) complexes [Mn(dicl)2(CH3OH)4] (3) and
586[Mn(indo)2(CH3OH)4] (4) were isolated upon interaction of
587Mn(II) with the NSAIDs. The present compounds 1 and 2 are
588the first manganese metallacrowns hosting nonsteroidal anti-
589inflammatory drugs. Studies concerning the biological relevance
590of such metallacrowns are quite rare in the literature;47,94−97
591therefore, such studies of the synthesized complexes may pos-
592sibly lead to the design of more potent therapeutic compounds.
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